Kiromic BioPharma (NASDAQ:KRBP) Trading Down 15.4%

Kiromic BioPharma, Inc. (NASDAQ:KRBPGet Free Report) traded down 15.4% during trading on Thursday . The company traded as low as $2.75 and last traded at $2.75. 3,620 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 6,605 shares. The stock had previously closed at $3.25.

Kiromic BioPharma Stock Performance

The stock’s fifty day simple moving average is $2.79 and its 200-day simple moving average is $2.00.

Kiromic BioPharma (NASDAQ:KRBPGet Free Report) last issued its quarterly earnings data on Friday, May 10th. The company reported ($1.00) earnings per share (EPS) for the quarter.

Kiromic BioPharma Company Profile

(Get Free Report)

Kiromic BioPharma, Inc, a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.

Featured Articles

Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.